Dr. Sadelain on CAR T-Cell Therapies

Michel Sadelain, MD, PhD, Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Stephen and Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center (MSK), discusses chimeric antigen receptor (CAR) t-cell therapies.

CAR-T-cell therapies are a new class of drugs that are utilized to engineer cells and to instruct those cells to attack tumors, explains Sadelain.

Sadelain is researching CD19, a target molecule that is expressed in many lymphomas and leukemia within the b-cell lineage. It is a surface molecule that can be effectively recognized by CARs. Once the molecule expresses the CAR it is guided toward the tumor and can attack and destroy it.